10 completed, 9 recruiting, 7 active not recruiting, 3 terminated. 21 Phase 2, 15 Phase 1, 1 Phase 3.
Follow Metastatic Colorectal Adenocarcinoma: new trials by email Literature Review of Metastatic Colorectal Adenocarcinoma trials Research Report on Metastatic Colorectal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-08-10 | 2026-09-09 |
| Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion - Colorectal Cancer, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 48 | 2026-02-02 | 2026-05-15 |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors PF-08032562, Fulvestrant, Cetuximab - Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-) | Phase 1 | Recruiting | Pfizer | 260 | 2025-12-23 | 2026-07-22 |
| Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer Fruquintinib, TheraBionic P1 - Metastatic Colorectal Adenocarcinoma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 102 | 2025-09-10 | 2025-11-10 |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2025-06-23 | 2026-09-09 |
| Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer Balstilimab, Biospecimen Collection, Botensilimab - Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 | Phase 1 | Recruiting | University of Southern California | 15 | 2025-01-15 | 2026-03-17 |
| Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer Balstilimab, Biopsy, Biospecimen Collection - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2024-11-01 | 2024-11-21 | |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-06-05 | 2026-09-23 |
| Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC Experimental, Active Comparator - CRC, Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 220 | 2024-01-01 | 2024-01-08 |
| Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2023-10-31 | 2024-09-19 | |
| Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation - Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 146 | 2023-10-09 | 2026-10-02 |
| Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy Balstilimab, Biospecimen Collection, Botensilimab - Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 28 | 2023-05-11 | 2026-09-01 |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer Pembrolizumab, Questionnaire Administration, Rintatolimod - Metastatic Colorectal Adenocarcinoma, Microsatellite Stable | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2022-02-01 | 2022-02-08 | |
| A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer Colorectal Cancer Peptide Vaccine PolyPEPI1018, Trifluridine and Tipiracil Hydrochloride - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Completed | Mayo Clinic | 15 | 2022-01-10 | 2026-10-07 |
| CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen Cetuximab, FOLFIRI, FOLFOX regimen - Metastatic Colorectal Adenocarcinoma | Phase 2 | Active not recruiting | University of Campania Luigi Vanvitelli | 219 | 2021-07-15 | 2025-05-25 |
| Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate - Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma | Phase 1 | Recruiting | Roswell Park Cancer Institute | 45 | 2021-06-08 | 2026-05-04 |
| Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders Biopsy, Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule - Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2021-02-22 | 2026-06-12 |
| Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer Trifluridine/Tipiracil, Bevacizumab - Metastatic Colorectal Adenocarcinoma | Completed | Hunan Cancer Hospital | 90 | 2020-11-01 | 2023-05-22 | |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Binimetinib, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Terminated | University of California, San Francisco | 2 | 2020-08-31 | 2023-01-09 |
Showing 20 of 35. Sign in to see all of them.
Colorectal Neoplasms (26) · Colonic Neoplasms (7) · Rectal Neoplasms (6) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Ovarian Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (27) · Neoplasms by Site (27) · Colonic Diseases (26) · Digestive System Diseases (26) · Digestive System Neoplasms (26) · Gastrointestinal Diseases (26) · Gastrointestinal Neoplasms (26) · Intestinal Diseases (26) · Intestinal Neoplasms (26) · Rectal Diseases (26) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1)
Magnetic Resonance Spectroscopy (9) · Bevacizumab (8) · Specimen Handling (8) · regorafenib (6) · Biopsy (5) · Cetuximab (5) · trifluridine tipiracil drug combination (5) · Fluorouracil (4) · Leucovorin (4) · Oxaliplatin (4) · balstilimab (4) · pembrolizumab (4) · Disulfides (3) · HMPL-013 (3) · Immunoglobulin G (3)
City of Hope Medical Center (4) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · Hunan Cancer Hospital (3) · Academic and Community Cancer Research United (2) · Roswell Park Cancer Institute (2) · Alliance for Clinical Trials in Oncology (1) · Assiut University (1) · Barbara Ann Karmanos Cancer Institute (1) · Beijing Biotech (1) · Centre Hospitalier Universitaire Dijon (1) · China Medical University, China (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Pfizer (1)
United States (25) · China (6) · France (2) · Italy (2) · Spain (2) · Belgium (1) · Canada (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
Marwan G Fakih (4) · Christos Fountzilas, MD (2) · John H Strickler (2) · Michael J Overman (2) · Amir A Jazaeri (1) · Andrea Cercek, MD (1) · Chloe E Atreya, MD, PhD (1) · Christine Parseghian (1) · Daniel H Ahn (1) · Diana Hanna, MD (1) · Fortunato Ciardiello (1) · Ji Zhu, M.D. (1) · Jingdong Zhang (1) · Jorge Ramos, DO (1)
PMID 31101691, PMID 31401903, PMID 33811727, PMID 35379611, PMID 36652155, PMID 36860319, PMID 36892833, PMID 37142372, PMID 37318379, PMID 37919668, PMID 37941353, PMID 38309721, PMID 38350888, PMID 39368039, PMID 40611889, PMID 42101296, PMID 42525921
P30CA015083 (3), P30CA033572 (3), 2015 (1), 2025 (1), P30CA014089 (1), P50CA221707 (1), R37CA282430 (1), U10CA180868 (1), UM1CA186688 (1), UM1CA186689 (1), UM1CA186691 (1)